EHA 2015 | The treatment of relapsed/refractory chronic lymphocytic leukemia
Barbara Eichhorst
• 12 Jun 2015
Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, summarises her highlights of the 20th Congress of the European Hematology Association (EHA), including the results of a phase 1b trial that showed the combination of venetoclax (ABT-199/GDC-0199) and rituximab induces deep responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL); and the long-term follow-up results of a trial that evaluated the safety and clinical activity of idelalisib in patients with relapsed or refractory CLL.
